Blog / glp 1
Semaglutide for MASH: What the ESSENCE Trial Shows and What to Track
What the ESSENCE trial found on semaglutide and fatty liver disease (MASH), what the FDA approved, and what to record for your provider.
By Peppy Team6 min read
Fatty liver disease rarely gets the attention that weight or blood sugar does. That changed in 2025, when a large trial and an FDA decision put semaglutide and the liver in the same headline.
This post explains what the ESSENCE trial found, what the FDA approved, and what is still unknown. It also covers how a GLP-1 tracker app can help you keep the kind of record that makes liver conversations with your provider easier. None of this is medical advice. Whether any treatment fits you is a decision for a licensed healthcare provider.
What MASH is, in plain words
MASH stands for metabolic dysfunction-associated steatohepatitis, formerly called NASH.
Here is the simple version:
- Steatosis means fat has built up in the liver.
- Hepatitis means the liver is inflamed.
- Fibrosis means scar tissue has started to form.
The FDA describes MASH as a serious, progressive liver disease. It is linked with obesity, type 2 diabetes, high triglycerides and high LDL cholesterol. Over time it can lead to cirrhosis, liver cancer or the need for a transplant. The FDA estimates that about 6% of U.S. adults have it.
The NIDDK notes that fatty liver disease is usually a silent condition with few or no symptoms. Doctors use blood tests, imaging and sometimes a liver biopsy to find it and to tell the milder form from MASH. The same page notes that weight loss can reduce fat, inflammation and fibrosis in the liver.
What the ESSENCE trial tested
ESSENCE is a phase 3 trial run by Novo Nordisk, the maker of semaglutide. Its first results were published in the New England Journal of Medicine in 2025 (Sanyal et al., PubMed 40305708).
The setup, in short:
- 1,197 adults with biopsy-confirmed MASH and moderate or advanced fibrosis (stage 2 or 3) were enrolled.
- They were randomly assigned to once-weekly semaglutide injections or a placebo, two to one.
- The full trial is planned to last 240 weeks.
- The published results are a planned interim look at week 72, covering the first 800 participants.
The main questions were about liver tissue itself, measured by biopsy. Did the inflammation resolve without the scarring getting worse? Did the scarring improve without the inflammation getting worse?
What the results showed
At week 72, the researchers reported these differences between the two groups:
| Outcome at week 72 | Semaglutide | Placebo |
|---|---|---|
| Steatohepatitis resolved, fibrosis not worse | 62.9% | 34.3% |
| Fibrosis improved, steatohepatitis not worse | 36.8% | 22.4% |
| Both resolved and improved | 32.7% | 16.1% |
| Average change in body weight | -10.5% | -2.0% |
Two things are worth noticing in that table.
First, the placebo group improved too. About a third of people on placebo saw their inflammation resolve. Trial participants on both sides were also working on diet and activity, so lifestyle changes clearly played a part.
Second, the difference was still large. The semaglutide group had roughly twice the rate of combined improvement.
What the FDA approved, and what "accelerated" means
In August 2025, the FDA approved Wegovy (semaglutide) injection for adults with MASH and moderate to advanced fibrosis, but not cirrhosis. It is meant to be used alongside a reduced-calorie diet and more physical activity.
The approval came through the accelerated approval pathway. That pathway lets a treatment for a serious condition reach patients earlier based on a surrogate measure, here the biopsy results. The FDA requires more data afterward to confirm a real clinical benefit.
That is why ESSENCE is still running. The FDA's announcement explains that the trial continues to week 240 to see whether the tissue improvements turn into fewer deaths, transplants and other liver events. The FDA also says that semaglutide promotes weight loss and possibly other mechanisms that are not fully understood, which may improve liver inflammation and scarring.
What is still unknown
It helps to be honest about the limits of the current evidence:
- Long-term outcomes are not in yet. Week 72 tissue results are encouraging, but the hard outcomes come later.
- Cirrhosis was not covered. The approval is for people without cirrhosis.
- Biopsy is the measure. Most people will not have repeat biopsies in daily care, so providers often lean on blood tests and imaging over time.
- Results vary. A percentage in a trial describes a group. It does not predict what happens for any one person.
Only your provider can judge whether any of this applies to you, and how your liver health should be monitored.
Why a good record matters for liver care
When your provider looks at a new lab result, the most useful context is what happened in the months before it.
Here is what is worth writing down if you are on a GLP-1 under a provider's care.
Doses and timing
- The date and time of each dose
- The dose your provider gave you, exactly as prescribed
- Any missed or late doses, and when you caught up
- Changes to your dose, with the date your provider made them
A trial like ESSENCE measured results at fixed time points. Your own record lets your provider line up your lab dates with how consistently you took your medication.
Weight and trend
The trial reported an average weight change, and weight loss is part of how the FDA explains the effect. A simple weight log, taken the same way each time, gives your provider a trend line rather than a single number from the clinic scale.
Side effects
Write down what you notice, when it started, how strong it felt and how long it lasted. Gastrointestinal effects were more common with semaglutide in the trial. Your provider is the one to interpret them. Your job is just to record them clearly.
Labs and appointments
Keep a short list of lab and imaging dates, such as liver blood tests or a liver scan, next to your dose history, and bring the reports to your visits.
Keeping the record in Peppy
If you would rather not juggle notes and spreadsheets, Peppy is a GLP-1 tracker app for iPhone that keeps these pieces in one place. You can set dose reminders, see your full dose history with missed and on-time doses, and chart your weight against a goal. Side-effect check-ins sit next to your doses, which makes trends easier to discuss, as covered in the weight, side effects and history guide.
There is also a semaglutide tracker page if that is your medication. For anyone working from a vial rather than a pen, the free peptide calculator shows how the vial strength, the water added and the dose your provider gave you turn into units on a syringe. It converts numbers only and never suggests a dose.
Peppy needs no account, and your data stays on your iPhone and your own iCloud backup.
Questions to bring to your provider
If liver health is part of your care, these questions can help you get more out of the visit:
- How will my liver be monitored over time, and how often?
- Which tests matter most in my situation?
- What should I record between visits that would help you?
- Are there side effects you want me to report right away?
The short version
The ESSENCE trial reported that semaglutide improved liver inflammation and scarring at 72 weeks in adults with MASH and moderate to advanced fibrosis. The FDA approved it for that use in 2025 under accelerated approval, with longer-term results still to come. The benefit seen in the trial is a group finding, and your provider is the one to judge what it means for you.
What you can control is the record. Clear dose dates, a steady weight log, honest side-effect notes and a list of lab dates give your provider the full picture at every visit.
More from the blog

glp 16 min read
FLOW Trial Explained: Semaglutide Kidney Outcomes and Tracking
What the FLOW trial found on semaglutide and chronic kidney disease, and which lab and dose records to bring to your provider.
- glp 1
- semaglutide
- tracking

glp 16 min read
SELECT Trial Explained: Semaglutide Heart Outcomes and Tracking
What SELECT found about semaglutide and heart risk without diabetes, and how a GLP-1 tracker helps you bring clean records to your provider.
- glp 1
- semaglutide
- tracking

semaglutide6 min read
Semaglutide Benefits: What the Evidence Says and How to Track Your Progress
A plain guide to semaglutide benefits backed by FDA approvals and research, what they do not promise, and how to track your own progress with your provider.
- semaglutide
- glp 1
- weight
